Sanofi to market Stendra in Africa,CIS,Turkey and ME for Erectile Dysfunction
Vivus Inc. announced that it has entered into a License and Commercialization Agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia. Sanofi will be responsible for obtaining regulatory approval in its territories. Sanofi intends to market avanafil under the tradename Spendra or Stendra.
.Under the terms of the agreement, Vivus is eligible to receive up to $61 million in upfront payments, regulatory and sales milestones. Vivus will also receive escalating royalties based on net sales over the life of the agreement.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins